scholarly journals Long-term follow-up after active surveillance or curative treatment: quality-of-life outcomes of men with low-risk prostate cancer

2017 ◽  
Vol 26 (6) ◽  
pp. 1635-1645 ◽  
Author(s):  
Lionne D. F. Venderbos ◽  
Shafak Aluwini ◽  
Monique J. Roobol ◽  
Leonard P. Bokhorst ◽  
Eric H. G. M. Oomens ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Treatment Quality ◽  
Life Outcomes ◽  
Risk Prostate Cancer ◽  
Low Risk Prostate Cancer ◽  
Long Term Follow Up

Long-Term Follow-Up After Penile Prosthesis Implantation—Survival and Quality of Life Outcomes

2019 ◽  
Vol 16 (11) ◽  
pp. 1827-1833
Author(s):  
Francesco Chierigo ◽  
Paolo Capogrosso ◽  
Federico Dehò ◽  
Edoardo Pozzi ◽  
Nicolò Schifano ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Penile Prosthesis ◽  
Life Outcomes ◽  
Prosthesis Implantation ◽  
Quality Of Life Outcomes ◽  
Long Term Follow Up

scholarly journals Long-term follow-up of urethral reconstruction for blunt urethral injury at a young age: urinary and sexual quality of life outcomes

2019 ◽  
Vol 15 (3) ◽  
pp. 224.e1-224.e6
Author(s):  
N. Baradaran ◽  
J.W. McAninch ◽  
H.L. Copp ◽  
K. Quanstrom ◽  
B.N. Breyer ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Young Age ◽  
Urethral Injury ◽  
Urethral Reconstruction ◽  
Life Outcomes ◽  
Sexual Quality Of Life ◽  
Long Term Follow Up

Toxicity, quality of life outcomes, and dosimetric impact in phase III trial of hypofractionated or standard fractionated proton therapy for low-risk prostate cancer patients: PCG GU 002.

2017 ◽  
Vol 35 (6_suppl) ◽  
pp. 48-48
Author(s):  
Matthew Q. Schmidt ◽  
Carlos E. Vargas ◽  
William F. Hartsell ◽  
Megan Dunn ◽  
Sameer R. Keole ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Low Risk ◽  
Phase Iii ◽  
Long Term Effects ◽  
Phase Iii Trial ◽  
Risk Prostate Cancer ◽  
Low Risk Prostate Cancer

48 Background: The purpose of this study is to identify differences in toxicity, quality of life (QOL), and dosimetric endpoints among patients with low-risk prostate adenocarcinoma treated with either standard fractionation or hypofractionation proton-beam therapy. Methods: We analyzed the results of the first 75 patients treated in our phase III trial comparing 38Gy relative biological effectiveness (RBE) in 5 fractions (fx) (n = 46) vs. 79.2Gy (RBE) in 44 fx. (n = 29). All patients had low-risk prostate cancer and were treated with proton radiation using fiducial markers and daily image guidance. We evaluated American Urological Association (AUA) Symptom Index, adverse events (AEs), and Expanded Prostate Index Composite (EPIC) domains at pretreatment and 3, 6, 12, 18, 24, 36 and 48 months. Doses to the prostate were selected based on similar long term effects to normal tissue based on an α/β = 3.5 for an EQD2 of 76Gy. Results: The median follow-up was 36 months for both groups; 23 (30%) patients reached a follow-up of 48 months. We observed a small difference in AUA score (3.2 vs. 8.6, p = 0.002) at 1-year favoring the 79.2Gy arm. AUA scores were not statistically different at 18 months and after. Similarly, EPIC Urinary symptoms favored the 79.2Gy arm at 1 year (92.3 vs. 84.5, p = 0.009) and 18 months (92.3 vs. 85.3, p = 0.03); bother scores were not significantly different at any other time points. G2 or higher GU toxicity was similar between arms (p = 0.8). No differences in EPIC Bowel symptoms, EPIC Sexual symptoms, or bowel G2 or higher toxicities were seen. One death was observed in the 38Gy arm due to an unrelated case of multiple myeloma. The bladder V80 (79.2Gy arm, p = 0.04) and V39 (38Gy arm, p = 0.05) were predictive for G2 or higher GU AE. There was no association observed between rectal dose and G2 or higher rectal toxicity. Conclusions: Patients treated in the hypofractionated and standard arms tolerated treatment well. A small and temporary difference in the GU domain was seen favoring the standard arm. As predicted long term effects on the GU domain and bowel were similar for both arms, suggesting that the α/β is similar to 3.5 for long term effects. Clinical trial information: 01230866.

Long-term follow-up after radiotherapy for prostate cancer with and without rectal hydrogel spacer: A pooled prospective evaluation of quality of life.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 39-39
Author(s):  
Zachary A Seymour ◽  
Stephanie Daignault ◽  
Walter Bosch ◽  
Hiram Alberto Gay ◽  
Jeff M. Michalski ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Repeated Measures ◽  
Organs At Risk ◽  
Logistic Models ◽  
Pooled Analysis ◽  
Long Term Follow Up

39 Background: Hydrogel spacers are a tool to improve dosimetry and overall quality of life with limited follow-up in men receiving radiotherapy for prostate cancer. This present study is a pooled analysis of a prospective cohorts with long-term follow-up quality of life (QOL) data with or without hydrogel spacers to minimize dose adjacent organs at risk. Methods: QOL was examined using the Expanded Prostate Cancer Index Composite (EPIC) to compare mean changes from baseline. A total of 215 patients from a randomized multi-institutional trial of radiation with or without hydrogel spacer with a QOL end-point were pooled with 165 non-randomized patients from a single institution with prospective QOL collection in both patients with or without hydrogel spacer. The proportions of men with minimally important differences (MIDs) relative to pre-treatment baseline in each domain were tested using repeated measures logistic models with pre-specified thresholds for clinically significant decline. Results: A total of 380 men were evaluated (64% with spacer and 36% without) with QOL data being available for 199 men beyond 24 months of follow-up (median: 39.5 months, range: 31-71.4 mo). Treatment with spacer was associated with less decline in average long-term bowel QOL (89.4 for control and 94.7 for experimental) with differences at > 2 years meeting the threshold of MID difference between cohorts (Bowel Score Difference from baseline: control = -5.1 spacer = 0.3 Diff = -5.4 p = 0.0003). When evaluated over time men without spacer were more likely to have 1xMID (5 points) declines in bowel QOL (p = 0.01). At long-term follow-up 1xMID was 36% without spacer vs 14% with spacer (p = 0.0006 OR = 3.5) while 2x MID was seen in 19% vs 6% (p = 0.008 OR = 3.6). The use of spacer was associated with improved bowel frequency (p = 0.002), reduced bleeding (p = 0.005) and less overall bowel problems (p = 0.007). Conclusions: In this pooled analysis of QOL after prostate radiotherapy with up to 5-years of follow-up utilization of a hydrogel spacer was associated with preservation of bowel QOL. This QOL benefit was preserved with long-term follow-up.

Sign in / Sign up

Export Citation Format

Share Document